MedinCell announced that its long-acting injectable malaria treatment is ready to enter into the stages of regulatory development.
Montpellier, France–based MedinCell conducted an in vivo proof of concept on cattle that demonstrated three-month mosquitocidal effectiveness in the injectable, long-acting formulation of Ivermectin using the company’s BEPO delivery technology.
The company designed the investigational mdc-STM product to reduce the transmission of the parasite responsible for Malaria through a killing effect on the vector mosquitoes when they bite treated people, according to a news release.
BEPO technology offers control over regular drug delivery at the optimal therapeutic dose for several days, weeks or months, beginning with the subcutaneous or local injection of a simple deposit of a few millimeters. In addition, it is fully bioresorbable, the company says.
MedinCell in March 2020 received a $6.4 million subvention over three years from global health agency Unitaid to conduct the formulation and preclinical activities for the malaria treatment.
